Head-to-head · WeighScore
Bodi Envi vs Omada Health
The verdict
Bodi Envi takes it — 71.8/100 to 55.6/100.
Bodi Envi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bodi Envi is a nationwide telehealth weight-loss provider offering physician-prescribed compounded semaglutide ($179/month) and tirzepatide ($249/month) at flat all-dose pricing with no consultation or…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bodi Envi | Omada Health |
|---|---|---|
| WeighScore | 71.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #88 | #435 |
| Semaglutide | $179/mo | Not disclosed |
| Tirzepatide | $249/mo | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #88 · C
Strengths
- Transparent flat pricing: compounded semaglutide $179/month and tirzepatide $249/month, all doses
- No consultation or membership fees
- Free 2-day shipping included; FSA and HSA eligible
- 24/7 secure provider messaging with same-day visits and prescriptions
- Personalized dose titration with side-effect management (Zofran available)
Where it loses points
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- No insurance billing — cash-pay only
- States served are not explicitly listed (features vary by state)
- No LegitScript certification visible on the site
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.